أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - esomeprazole - tablets gastro-resistant - 40 milligram - proton pump inhibitors

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - imatinib mesilate - film coated tablet - 400 milligram - protein kinase inhibitors

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - imatinib mesilate - film coated tablet - 100 milligram - protein kinase inhibitors

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - combinations - clopidogrel/acetylsalicylic acid teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid teva is a fixed‑dose combination medicinal product for continuation of therapy in:non‑st segment elevation acute coronary syndrome (unstable angina or non‑q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule - 10 milligram(s) - proton pump inhibitors; omeprazole

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule - 20 milligram(s) - proton pump inhibitors; omeprazole

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule, hard - 40 milligram(s) - proton pump inhibitors; omeprazole

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 20 milligram(s) - proton pump inhibitors; pantoprazole

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40 milligram(s) - proton pump inhibitors; pantoprazole

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

teva b.v.  - clopidogrel (as hydrochloride) - myocardial infarction; peripheral vascular diseases; stroke - antithrombotic agents - clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillation in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.